Edith A. Perez, MD
Mayo Clinic
18
1
17
N/A
0
10
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+24 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (18)
Showing 10 of 18 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Donald W. Northfeld, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Kathy S. Albain, MD
Loyola University
Shared therapeutic areas:
Worked with same sponsors:
James N. Ingle, MD
Mayo Clinic in Rochester
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
John D. Hainsworth, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (18)
Showing 18 of 18 trials
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer
Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer
Vinorelbine in Treating Older Women With Stage IV Breast Cancer
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer
All 18 trials loaded